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Abstract
Notwithstanding rapid advances of nanotechnology in diagnostic imaging and drug delivery, the 
engineered nanocarriers still exhibit substantial lack of hemocompatibility. Thus, when injected 
systemically, nanoparticles are avidly recognized by blood leukocytes and platelets, but the 
mechanisms of immune recognition are not well understood and strategies to mitigate these 
phenomena remain underexplored. Using superparamagnetic dextran iron oxide (SPIO) 
nanoworms (NWs) we demonstrate an efficient and predominantly complement-dependent uptake 
by mouse lymphocytes, neutrophils and monocytes from normal and tumor bearing mice in vitro. 
Following intravenous injection into wild type mice, blood leukocytes as well as platelets became 
magnetically labeled, while the labeling was decreased by 95% in complement C3-deficient mice. 
Using blood cells from healthy and cancer patient donors, we demonstrated that neutrophils, 
monocytes, lymphocytes and eosinophils took up SPIO NWs, and the uptake was prevented by 
EDTA (a general complement inhibitor) and by antiproperdin antibody (an inhibitor of the 
alternative pathway of the complement system). Cross-linking and hydrogelation of SPIO NWs 
surface by epichlorohydrin decreased C3 opsonization in mouse serum, and consequently reduced 
the uptake by mouse leukocytes by more than 70% in vivo. Remarkably, the cross-linked particles 
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did not show a decrease in C3 opsonization in human serum, but showed a significant decrease 
(over 60%) of the uptake by human leukocytes. The residual uptake of cross-linked nanoparticles 
was completely blocked by EDTA. These findings demonstrate species differences in 
complement-mediated nanoparticle recognition and uptake by leukocytes, and further show that 
human hemocompatibility could be improved by inhibitors of complement alternative pathway 
and by nanoparticle surface coating. These results provide important insights into the mechanisms 
of hemocompatibility of nanomedicines.
Graphical abstract
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Nanomedicine holds great promise for medical imaging and site-specific drug delivery with 
engineered nanoparticles (NPs);1,2 however, intravenously injected NPs encounter many 
biological barriers before they can reach the desired targets within the vasculature or beyond. 
Among these, elements of the innate immune system, and notably blood leukocytes and 
tissue macrophages, are key players intercepting blood-borne nanoparticles and 
pathogens.3–5 The propensity of macrophages and related immune cells to rapidly recognize 
and sequester nanoparticles can offer an unprecedented opportunity to selectively delivery of 
antigens and therapeutic agents to such cells for imaging and therapy. On the other hand, 
rapidly intercepting and eliminating nanomedicines is problematic if the intended target site 
for therapeutic intervention lies elsewhere. Accordingly, this may decrease specificity of 
targeting and imaging, provoking untoward responses and inducing off-target toxicities.7,8
The complement system is a critical component of the innate immunity accounting for about 
5% of globulins in serum and is responsible for recognizing, eliminating, and destroying 
pathogens.4 Activation of the complement on the surface of a foreign agent proceeds via the 
classical pathway (CP), lectin pathway (LP) or alternative pathway (AP), and converges to 
form highly reactive thioester C3b that covalently binds to reactive groups (e.g., amines and 
hydroxyls) on the surface of the activator. Opsonization by C3b triggers particle recognition 
by phagocytic cells through their complement receptors,3,5 whereas soluble cleavage 
byproducts C3a and C5a are potent anaphylatoxins and proinflammatory molecules with low 
nanomolar affinity for their corresponding receptors.6 Accordingly, complement activation 
plays an important role in nanoparticle clearance and adverse immune reactions.7,8 
Numerous nanoplatforms have been shown to activate complement in vitro and in vivo.8–23 
Uncontrolled complement activation in human patients may contribute to infusion-related 
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reactions, and this has been demonstrated in the case of various clinically approved 
nanopharmaceuticals (Doxil, Feridex, Taxol).
Superparamagnetic iron oxide (SPIO) was one of the first clinically approved 
nanodiagnostics employed in magnetic resonance imaging (MRI) contrast agent. SPIO is 
also actively being explored as part of complex nanoassemblies and multifunctional 
theranostic nanomedicines.24 SPIO consists of negatively charged magnetite-maghemite 
(Fe3O4 and γ-Fe2O3) crystals coated with a polysaccharide polymer (usually dextran or 
carboxymethyl dextran). Others25 and our group26,27 reported synthesis and characterization 
of elongated worm-like SPIO (dubbed nanoworms) made from 20 kDa dextran chains. 
Recently, we reported that SPIO NWs potently activate complement in mouse and human 
sera leading to the deposition of C3b/iC3b on the nanoparticle surface.28 In mice, SPIO 
NWs activate the lectin pathway due to the initial binding of mannose binding lectin (MBL-
A/C) and MBL-associated serine protease MASP-2. In humans, the lectin pathway is also 
activated, but the majority of activation comes from a direct surface-mediated increase of the 
alternative pathway turnover.28
Here we used SPIO NWs to study the role of complement in the uptake by leukocytes of 
mouse and the human blood. The unique advantage of magnetic nanoparticles for such 
experiments is the easy magnetic isolation and enrichment of cells, thus facilitating 
mechanistic studies. Albeit the uptake of nanoparticles by blood leukocytes has been 
reported before,29–33 the role of complement in the leukocyte uptake of iron oxides has not 
been conclusively demonstrated.
RESULTS
We prepared non-cross-linked 20 kDa dextran-coated SPIO NWs by a modified Molday 
precipitation method34 as described by us earlier.26 The particles appeared as worm-like 
structures by TEM (Figure 1A), with multiple electron-dense magnetite-maghemite cores 
per nanoparticle embedded in dextran chains and a hydrodynamic diameter of 111.4 ± 28 
nm. SPIO NWs were preincubated in fresh mouse serum for 15 min and washed by 
ultracentrifugation. C3 was detected on the particles by a dot blot assay (Figure 1B) using an 
antibody that recognizes a variety of C3 fragments (C3b, iC3b, C3d etc.).28 There was a 
significant deposition of C3 in wild-type (WT) mouse serum (Figure 1C), but not in C3−/− 
mouse serum or in serum pretreated with 4 mM EDTA (a general complement inhibitor).
1. In Vitro Uptake of SPIO NW by Mouse Leukocytes Is C3 Dependent
For in vitro uptake experiments, mouse blood cells were washed in PBS in order to remove 
excess of heparin, an anticoagulant and complement inhibitor. SPIO NWs was preincubated 
with serum and then added to the washed mouse blood cells (leukocytes, red blood cells and 
platelets) obtained from C45/BL5 or BALB/c mice. The cells that bound or internalized 
SPIO NWs were isolated using a Mini MACS magnetic column (Figure 2A). The isolation 
sensitivity is high, because SPIO NWs have very high magnetization values,26 and the 
magnetic beads are capable of isolating rare cells, for example circulating tumor cells.35 The 
eluted cells were concentrated on a slide and stained with antidextran antibody and anti-
CD11b antibody (complement receptor 3 (CR3)), and the nuclei were stained with Hoechst. 
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We used nuclear shape to identify and enumerate the magnetically labeled cells (Figure 2B). 
Nuclear shape is one of the classical parameters for leukocyte identification,36 and has been 
found to be a reliable parameter for leukocyte type classification.37,38 We verified that 
nuclear shape classification by microscopy highly correlates with forward scattering-side 
scattering classification by flow cytometry (Supporting Information). The majority of 
leukocytes were CD11b+ neutrophils, albeit lymphocytes and monocytes also showed 
dramatic uptake (Figure 2C,D). In order to test the role of complement in the leukocyte 
uptake, SPIO NWs were preincubated with sera from C3−/− mice before adding to the 
washed blood cells. As a result, the number of magnetically labeled neutrophils decreased 
by 90%, and the number of monocytes decreased by ~70% (Figure 2C,D).
Since nanoparticles are being actively explored for tumor drug delivery and imaging, we 
questioned whether SPIO NWs are also taken up by leukocytes from tumor-bearing mice, 
and whether the uptake is complement-dependent. We used 4T1 breast cancer allograft 
model in BALB/c mice, which metastasizes within 1 week postinjection.39 Mice with 5–10 
mm diameter tumors had 3–5 times more neutrophils compared to nontumor-bearing mice, 
and correspondingly there were 3 times more CD11+ neutrophils that took up SPIO NWs 
(Figure 2E,F). The number of magnetically labeled leukocytes decreased by 95% when 
SPIO NW was preincubated in C3−/− serum (Figure 2E,F), confirming that leukocytes in 
tumor mice take up SPIO NWs in a complement-dependent manner.
2. SPIO NWs Are Internalized after Intravenous Bolus by Mouse Leukocytes, and the 
Uptake Is C3 Dependent
In order to determine the uptake of SPIO NWs by leukocytes in vivo, nanoparticles were 
injected as a 0.1 mg bolus into normal C57/BL6 mice. Following the injection, we collected 
heparinized blood at different time points (10 min, 1h and 24 h) and isolated the cells as 
outlined in Figure 3A. At 10 min postinjection, a significant proportion of neutrophils, 
lymphocytes and monocytes were magnetically labeled, albeit the ratio between neutrophils 
and lymphocytes varied between experiments. At 1h postinjection, as many as 16.8 ± 4.9% 
(n = 3 mice) of total blood leukocytes were magnetically labeled. Results of a representative 
experiment (Figure 3B) show that the majority of magnetically isolated cells at 1h 
postinjection were neutrophils. The number of magnetically labeled leukocytes in circulation 
decreased 5-fold at 24 h postinjection. Parallel injection experiments in C3−/− mice (C57/
BL6J background) showed that there were 95% less magnetically labeled neutrophils and 
lymphocytes compared to normal C57/BL6 mice at 1h postinjection (Figure 3B).
Since the number of circulating magnetically labeled leukocytes dropped dramatically at 24 
h, we questioned whether SPIO NWs uptake accelerated the clearance of leukocytes. The 
total leukocyte count in blood did not change after the injection (not shown). We isolated 
leukocytes from normal C45/BL6 mice and prelabeled them with carboxyfluorescein 
succinimidyl ester (CFSE, Figure 4A). CFSE effectively and irreversibly labels the 
cytoplasm of cells and can be used for in vivo cell tracking and proliferation.40 The CFSE 
labeled leukocytes were incubated with SPIO NWs as described in Figure 2A and the 
magnetically labeled leukocytes were isolated using a MACS column and injected into 
another mouse (0.3–0.5 million cells/animal). For a control, CFSE labeled leukocytes that 
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were not trapped in the column were injected into a control mouse. In both groups, the cells 
did not form clusters before the injection. According to Figure 4B, CFSE-labeled leukocytes 
were present in blood at 10 and 60 min postinjection in both groups. At 24 h postinjection, 
CFSE-labeled leukocytes in both groups were absent from peripheral blood. At 24 h post 
injection, CFSE labeled leukocytes were found in the spleen, but not in the liver or kidney 
(Figure 4C). Inspection of lungs, lymph nodes or bone marrow did not reveal CFSE labeled 
cells (not shown). Because of the short duration of this experiment, the numbers of cells in 
organs reflect true distribution rather than cell proliferation. We conclude that the observed 
evacuation of magnetically labeled leukocytes from blood (Figure 3B) is the part of normal 
process of leukocyte recirculation.40,41
In addition to leukocytes, we observed that mouse platelets also became magnetically 
labeled in vitro and in vivo (Figure 5A). No platelets were captured by MACS column from 
control blood (not shown). There was a significant drop in the number of magnetically 
labeled platelets in C3−/− serum in vitro and in C3−/− mice in vivo (Figure 5B,C; E,F). 
Interestingly, a significant proportion of platelets were associated with leukocytes in wild-
type experiments in vitro and in vivo, and much less association was observed in C3−/− 
experiments (Figure 5A,D).
3. The Uptake of SPIO NWs by Human Leukocytes is C3 Dependent
Next, we investigated the role of complement in human leukocyte uptake. We used washed 
blood leukocytes obtained from healthy male and female donors. The human leukocyte 
uptake studies, with the exception of the conditions of incubation of SPIO NWs with serum 
(see Materials and Methods), were performed exactly as mouse experiments. According to 
Figure 6A, neutrophils, monocytes, lymphocytes and eosinophils became magnetically 
labeled after incubation with SPIO NWs in vitro. Since there are no C3-deficient human 
individuals, and commercially available C3-depleted sera often contain additives and 
complement blockers, we used complement inhibitors in order to inhibit C3 opsonization of 
SPIO NWs. In humans, SPIO NWs activate the lectin and the classical pathway (in some 
individuals with antidextran antibodies through the classical pathway), but the alternative 
pathway is self-sufficient and responsible for the majority of C3 deposition (summarized in 
Figure 6B).28 The alternative pathway (AP) requires presence of properdin (factor P), which 
is present in blood at ~20 μg/mL and stabilizes AP-derived C3 convertases.42 Human C3 
deposition on SPIO NWs (Figure 6C) was decreased by over 95% using 4 mM EDTA (an 
inhibitor of all complement pathways) and by 70% using antiproperdin (anti-P) antibody (a 
specific inhibitor of the AP43). The number of magnetically labeled cells of all types was 
decreased as much as 90% in both EDTA-treated serum and anti-P-treated serum (Figure 
6D,E). Similar to mouse experiments, neutrophils were highly dependent on C3 
opsonization for the uptake, but monocytes, lymphocytes and eosinophils also showed 
dependency on the complement (Figure 6D,E). In addition to normal healthy donor blood, 
we also tested the role of complement in the uptake of serum-preincubated SPIO NWs by 
blood cells from metastatic breast cancer patient. As shown in Figure 6F, there was an 
efficient uptake by cancer patient’s leukocytes and complete blockade by EDTA and 
antiproperdin antibody.
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4. Cross-Linking and Hydrogelation of Dextran Coat Blocks Leukocyte Uptake 
Independently of Complement Activation
Reaction of dextran hydroxyls with epichlorohydrin leads to hydrogel coated cross-linked 
nanoworms (CL-NWs, Figure 7A).26,27,44 Previously we demonstrated that cross-linking 
blocks the lectin pathway activation in mouse serum and consequently decreases 
complement C3 opsonization28 and decreases macrophage recognition in mice.45 We set out 
to determine whether cross-linking blocks the leukocyte uptake in mouse and human sera. 
The cross-linking minimally changed the size of nanoworms (114 nm before and 83 nm 
after) and did not change the worm-like shape of the nanoparticles (Figure 7B). Cross-
linking resulted in a formation of poly(2-hydroxypropyl ether) hydrogel as measured by 
iodine assay,26 with 0.6 mg of ethylene oxide per milligram of iron (Figure 7C). There was a 
significant (70%) decrease in C3 opsonization of CL-NWs in mouse serum compared to 
non-cross-linked SPIO NWs (Figure 7D). Intravenous injection of CL-NWs into normal 
C57/BL6 mice showed over 70% decrease in the number of magnetically labeled leukocytes 
in mouse blood compared to non-cross-linked SPIO NW (Figure 7E,F). In human serum, 
however, cross-linking did not decrease C3 opsonization of CL-NWs (Figure 7G), likely due 
to the predominant role of the alternative pathway in human serum.28 At the same time, 
incubation with human blood cells from a healthy donor showed 60% decrease (30–70% 
range for 5 different blood donors, not shown) in the number of magnetically labeled cells 
after 1h incubation (Figure 7H,I). The C3 opsonization and the residual uptake of CL-NWs 
by human leukocytes was inhibited by EDTA (Figure 7G,I). These data suggest that cross-
linked hydrogel coating partially inhibits the complement-dependent uptake of 
nanoparticles.
DISCUSSION
This report demonstrates that recognition of iron oxide nanoparticles by leukocytes and 
platelets is mediated exclusively via complement C3 in normal donors and cancer patients, 
and across different species (mice and humans). SPIO NWs are different from the clinical 
(now abandoned) SPIO Feridex: the latter was manufactured with 10 kDa dextran, and the 
particles have a spherical rather than a worm-like shape. Nevertheless, Feridex showed 
significant complement-related toxicity in clinical use, and the injection of this agent into 
rats at 20 mg Fe/kg resulted in labeling of 5% of leukocytes in vivo.30 Therefore, we suggest 
that complement-triggered leukocyte uptake could be relevant to many types of iron oxide-
based MRI agents. Numerous other nanoplatforms including gold, polymeric nanoparticles, 
carbon nanotubes, liposomes and micelles have been shown to activate complement in vitro 
and in vivo,8–23 and it remains to be elucidated whether these nanomaterials are also 
sequestered by leukocytes via complement-mediated mechanisms. We demonstrated that 
immune uptake of nanoparticles by human leukocytes can be prevented by inhibitors of the 
alternative pathway of complement (antiproperdin antibody), which could make the 
complement cascade an attractive target to improve hemocompatibility of nanomaterials. At 
the same time, we demonstrate that surface cross-linking could be an independent strategy to 
decrease leukocyte uptake, regardless of the level of complement activation. The strong 
inhibition of CL-NW uptake by human leukocytes despite C3 opsonization is a 
counterintuitive result, but is in line with previous observations. Thus, studies using 
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liposomes bearing PEG 2000 showed that although complement is activated, the steric 
barrier of PEG is strong enough to prevent the binding of C3 opsonized liposomes to 
macrophages.21 Another study demonstrated the lack of correlation between C3 
opsonization and long-circulating properties of PEGylated liposomes.46 The reasons why 
cross-linked polymer coating renders nanoparticles less recognizable by leukocytes despite 
C3 opsonization need to be further investigated, but it could be speculated that hydrogel 
coatings change conformation of surface bound C3 and/or reduces interaction between C3 
(C3b and iC3b) and complement receptors due to steric effects.
We still do not know much about the receptors responsible for recognition of complement-
opsonized SPIO NWs by leukocytes and platelets. Neutrophils express complement 
receptors C1qR, CR1, CR3, and CR4 that are responsible for phagocytosis of bacteria via 
C3b/iC3b recognition.47 Lymphocytes express complement receptor CR2, which is the 
receptor for C3d and is responsible for antigen presentation on B-lymphocytes and cell 
adhesion of T-lymphocytes,48,49 and CR1, which is responsible for capturing, 
postprocessing and trafficking of C3b-opsonized pathogens. In case of platelets, it is not 
clear whether they express classical complement receptors. Several reports suggest that C3b-
opsonized pathogens could bind to platelets via glycoprotein GpIIb/IIIa.50,51 Another 
possibility is P-selectin, which can mediate platelet adhesion to immobilized C3b.52 
Interestingly, we observed that many platelets adhere to neutrophils. C3a and C5b-9 activate 
platelets,53,54 and activated platelets are prone to form heteroaggregates with leukocytes via 
the platelet P-selectin and the leukocyte P-selectin glycoprotein ligand-1, and/or GpIIa and 
complement receptor 3.55,56 Accordingly, the interaction between leukocytes and platelets 
due to complement-mediated processes could be an interesting and unexpected twist to 
nanoparticle behavior in vivo. To fill this gap of knowledge, we are currently performing 
studies on the role of the complement receptors in the recognition and uptake.
The consequences of complement activation and subsequent immune recognition by 
leukocytes and platelets could be far reaching. Uncontrolled complement activation is 
known to cause inflammation,4 immune cell activation,57 increase vascular permeability58 
and even trigger tumor growth.59,60 That, together with the known ability of neutrophils, 
eosinophils, monocytes and even platelets to accumulate in pathological sites may play a 
critical role in pathogenesis of cancer and other disease.61–64 For instance, neutrophils could 
contribute to tumor growth through complex processes including elastase and properdin 
release.65 The latter may further enhance intratumoral complement activation and accelerate 
tumor growth by promoting angiogenesis as well the recruitment of immunosuppressive 
cells.66 Understanding the nanomaterial-mediated complement activation together with the 
role of complement in the crosstalk between activated platelets and leukocytes may further 
unravel the molecular basis of pulmonary hypertension, which is known to occur on infusion 
of nanomedicines in some individuals.67 On the other hand, careful exploitation of 
complement-mediated interception of blood-borne particles by leukocytes could offer better 
opportunities for delivery of drugs and contrast agents across many biological barriers by 
leukocyte “hitchhiking”.
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CONCLUSIONS
We demonstrated that blood leukocytes internalize iron oxide nanoworms via complement-
dependent mechanisms in mice and in humans, and showed that hemocompatibility can be 
improved either by the inhibition of the complement system, and notably the alternative 
pathway, or by dextran hydrogelation. In view of the ubiquitous role of complement in 
inflammation and disease, it is critical to further understand mechanisms of complement 
activation and complement-mediated uptake of nanoparticles in order to design more safe 
and efficient nanomedicines.
MATERIALS AND METHODS
Materials
All chemical reagents used for nanoparticle synthesis, including iron salts and 15–25-kDa 
dextran, were purchased from Sigma-Aldrich (St Louis, MO, US). Cell culture media were 
purchased from Corning Life Sciences. Antidextran DX-1 antibody was purchased from 
StemCell Technologies (Vancouver, BC, Canada). Goat antimouse and goat antihuman 
complement C3 polyclonal antibodies were purchased from MP Biomedicals (Solon, OH). 
Mouse monoclonal antiproperdin antibodies were purchased from Quidel (San Diego, CA). 
All fluorescent secondary antibodies for immunostaining were from Thermo Fisher 
Scientific. Copper grids (300 mesh) were purchased from Electron Microscopy Sciences 
(Hatfield, PA, US). BALB/c mice were bred in an animal vivarium at the University of 
Colorado Denver Anschutz Medical Campus according to the IACUC approved breeding 
protocol. The BALB/c breeder mice were purchased from Charles River Laboratories 
International, Inc. (Wilmington, MA). C3−/− mice (B6;129S4-C3tm1Crr/J) were obtained 
from Dr. Holers and bred in house. C57BL6 mice (Charles River) were used as a control for 
knockout experiments.
SPIO NWs Preparation and Cross-Linking
NWs were synthesized using a one-pot Molday and MacKenzie34 precipitation method 
using dextran, Fe(III) chloride and Fe(II) chloride as described previously.26 Nanoparticles 
were filtered through a 0.45-μm filter and stored sterile at 4 °C. Nanoparticles were cross-
linked using epichlorohydrin in a two-step harsh cross-linking procedure as described 
previously.26 Transmission electron microscopy (TEM) imaging was conducted to visualize 
the NWs using a FEI Tecnai electron microscope at a 100 kV working voltage. Size was 
determined using a NanoSight instrument (Malvern Instruments Ltd., Malvern, UK) after 
diluting 1 mg/mL solution of particles in sterile double distilled water 10 000 times. The 
data were reported as number weighted mean.
NWs Uptake In Vitro
For uptake experiments, blood from nontumor-bearing and 4T1 tumor-bearing mice was 
obtained by cardiac puncture. Sodium EDTA or heparin anticoagulated blood from healthy 
male and female volunteers was obtained from Bioreclamation LLC (Baltimore, MD). 
Sodium EDTA anticoagulated blood from anonymous metastatic triple-negative cancer 
patient was obtained from Moores UCSD Cancer Center according to an approved 
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Institutional Research Board (IRB) protocol. Before incubation with SPIO NWs, the blood 
cells were thoroughly washed with 1% (w/v) BSA-PBS to remove anticoagulated plasma. 
SPIO NWs were incubated with mouse sera at room temperature for 15 min or human sera 
at 37C for 30 min. For complement inhibition in human serum, either EDTA (4 mM) or 
antiproperdin antibody (1:10 dilution) was added to serum for 15 min prior to the addition of 
SPIO NWs. At the end of incubation, the SPIO NWs-serum mix was added to the washed 
blood and incubated at 37°C for 1 h. The blood was then washed by centrifugation to 
remove the NWs, and the cells with internalized SPIO NWs were collected using Miltenyi 
Biotec Mini MACS magnetic columns. The eluted cells from different groups were 
suspended in equal amounts of 1% (w/v) BSA-PBS and were concentrated on glass slides 
using cytospin (Thermo Fisher Scientific). The slides were then fixed with 10% (v/v) 
formalin in PBS and stained with Hoechst nuclear stain (Thermo Fisher). Main leukocyte 
types were counted under fluorescent microscope. Leukocyte types nuclear shape has been 
used to differentiate between lymphocytes (round shape), monocytes (kidney shape), 
neutrophils (multilobe, segmented shape) and eosinophils (bilobe nucleus connected by a 
thin bridge).36 Each experiment yielded 2–3 slides, and on each side, 10–20 random 
microscopic areas were captured under ×200 magnification. Between 500 and 1000 cells 
were counted in order to calculate the percentage of each leukocyte type.
Dot Blot C3 Binding Assay
For binding assay of complement C3 in mouse and human serum, SPIO NWs were 
incubated with serum as described above. At the end of incubation, particles were washed 3 
times with 1X PBS by centrifugation at 55 000g at room temperature using Beckman 
Optima TLX ultracentrifuge. The pellets were resuspended in 20 μL PBS, and 2 μL aliquots 
were applied in triplicate onto a nitrocellulose membrane. The membranes were blocked 
using 5% (w/w) nonfat dry milk in PBS-T (1 × PBS with 0.1% Tween 20) for 1 h at room 
temperature, probed with corresponding primary antibodies for 1 h at room temperature, 
followed by washing the membranes 3 times with PBS-T, and finally 1 h incubation with the 
corresponding IRDye 800CW-labeled secondary antibodies against the primary antibody 
species. After immunoblotting, the membranes were visualized using an Odyssey infrared 
imager (Li-COR Biosciences, Lincoln, NE, US). The integrated dot intensity in the scanned 
images was quantitatively analyzed using ImageJ software and plotted using Prism 6 
software (GraphPad Software, Inc. La Jolla, CA, US).
Nanoparticle Uptake In Vivo
NWs were injected as a 0.1 mg bolus via tail vein injection into WT and C3KO C57/BL6 
mice. Following the injection, blood was collected via retro-orbital bleeding at different time 
points (10 min, 1h and 24 h) using heparin as anticoagulant. Blood was washed, and the 
cells internalized with SPIO NWs were collected employing Miltenyi MiniMACS magnetic 
columns and concentrated on slides as described above. The slides were then fixed with 10% 
(v/v) formalin in PBS and stained to enable differential counting.
Leukocyte Labeling
Peripheral blood was collected from BALB/c mice by cardiac puncture using heparin as 
anticoagulant. Blood was centrifuged at 2000g for 5 min at room temperature, the 
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supernatant was discarded and red blood cells were lysed with RBC Lysis Buffer Solution 
(eBioscience, San Diego, USA). Leukocytes were washed 2 times with 1 × DPBS (Corning, 
Manassas, USA). Leukocytes (1 × 106 cells/mL) were labeled with 10 μM 
carboxyfluorescein succinimidyl ester CFSE (eBioscience) at room temperature for 8 min. 
Reaction was blocked with 2% fetal calf serum, and the cells were washed in 1 × DPBS 2 
times. Resuspended leukocytes were incubated with 0.1 mg/mL SPIO NWs (preincubated 
with mouse serum as described above) at 37 °C with gentle shaking for 1 h. SPIO NWs 
labeled leukocytes were isolated with MiniMACS column; both magnetic and non magnetic 
fraction were collected. Mice were injected with 0.5–1 × 106 leukocytes in 100 μL PBS via 
intravenous injection. Blood was collected from the periorbital plexus at 1 min, 10 min, 60 
min, 240 and 1440 min postinjection and CFSE positive cells were counted with 
hemocytometer.
Immunofluorescence
The slides were blocked with 10% (v/v) goat serum and incubated with antidextran antibody 
and either CD11b or CD41antibodies for 1 h at RT. At the end of incubation, slides were 
washed with 0.1% PBS-T and incubated with goat antimouse Alexa Fluor 488 and goat 
antirat Alexa Fluor 594 secondary antibodies along with Hoechst to stain the nucleus at 
room temperature for 1 h. The slides were washed to remove excess antibody and observed 
under a Nikon inverted microscope (Nikon Eclipse TE300) at 400× magnification. Images 
were captured using an attached CCD camera and the differential counting was done based 
on the shape of the nucleus.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Characterization of SPIO NWs and complement activation in sera: (A) Size of SPIO NWs as 
determined with transmission electron microscopy and dynamic light scattering. (B) Dot 
blot assay of complement C3 deposition on NWs. Following incubation with mouse serum, 
NWs were washed and analyzed for complement C3 binding as described previously.26 (C) 
The deposition was absent in 4 mM EDTA supplemented wild-type (WT) serum and in C3-
KO serum.
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Figure 2. 
Complement dependent uptake of SPIO NWs in vitro: (A) Workflow of in vitro uptake 
experiments. (B) Magnetically isolated blood cells were identified by the nuclear shape. N = 
neutrophil; M = monocyte; L = lymphocyte; P = platelet, (C,D) Uptake of SPIO NWs 
preincubated in normal (WT) or C3-deficient (C3KO) sera by leukocytes derived from 
nontumor bearing C57/BL6J mice. Cells were stained with antidextran antibody (SPIO 
NWs, green) and anti-CD11b antibody (complement receptor CR3, red). (E,F) Uptake of 
SPIO NWs by leukocytes derived from 4T1 tumor-bearing BALB/c mice. In both normal 
and tumor-bearing mice, leukocyte uptake was highly dependent on C3. Neutrophils were 
the predominant cells that internalized SPIO NWs in normal and tumor-bearing mice. One 
representative microscope field out of 10–15 is shown. Each experiment was repeated at 
least 3 times. All colors were enhanced by ImageJ software to the same extent for visual 
clarity.
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Figure 3. 
Complement dependent uptake of SPIO NWs by mouse leukocytes in vivo: SPIO NWs were 
injected into C3-deficient and control mice. (A) Workflow of in vivo experiments. (B) 
Results from one representative in vivo experiment (total N = 4) is shown. Cells were 
enumerated by their nuclear shape as described in Figure 2. The uptake by all cell types was 
decreased in C3 deficient mice.
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Figure 4. 
Circulation and organ distribution of magnetically labeled leukocytes: (A) Workflow of ex 
vivo cell labeling of leukocytes with CFSE or CFSE and SPIO NWs (full description in 
Materials and Methods). Cells were injected into mice at 0.5 × 106 cells per mouse. (B) 
Levels of the circulating CFSE-labeled cells measured by sampling blood and counting the 
fluorescent cells under microscope. Cells in both groups disappeared from circulation at 24 
h postinjection. Data from a representative experiment (out of 3) are shown. (C) CFSE/SPIO 
NWs labeled cells accumulated in the spleen, but not in the liver or kidneys. Control 
(nonmagnetically labeled cells) cells showed similar distribution (not shown).
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Figure 5. 
Complement dependent binding of SPIO NWs to mouse platelets in vitro and in vivo: SPIO 
NWs were incubated with washed mouse blood as described in Figure 1A, or injected into 
mice as described in Figure 2A. The magnetically isolated cells were stained for dextran on 
SPIO NWs (green) and CD41 (platelet marker). Platelets were counted based on the CD41 
staining. (A–C) Platelets became magnetically labeled after incubation with SPIO NWs in 
normal serum but not in C3KO serum. (D–F) Platelet became magnetically labeled after 
injection into normal mice but not C3 KO mice. In both in vitro and in vivo experiments, 
there were solitary scattered platelets as well as platelets bound to the cells surface. Images 
show representative microscopical fields, out of 10 counted. The experiments were repeated 
at least 2 times.
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Figure 6. 
Complement dependent uptake of SPIO NW in human serum: SPIO NWs were incubated 
with human blood cells and isolated as described in Figure 1A. (A) A representative 
microscopic field (high magnification) shows leukocytes magnetically labeled with SPIO 
NWs. E = eosinophil, N = neutrophil; M = monocyte. (B) Activation of complement in 
human sera by NWs is mostly via the alternative pathway.28 Properdin (P) is a serum factors 
that stabilizes the AP convertase C3bBb. (C) Complement C3 deposition in human serum 
was inhibited by EDTA or anti-Properdin Ab. (D,E) Complement dependent uptake by 
leukocytes from blood of a healthy donor. (F) Complement dependent uptake by leukocytes 
from blood of a breast cancer patient.
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Figure 7. 
Cross-linking of dextran shell decreases leukocyte uptake in mice and humans: (A) SPIO 
NWs were cross-linked with epichlorohydrin in order to obtain hydrogel coated CL-NWs. 
(B) Size and shape of nanoparticles was not significantly affected by the cross-linking. (C) 
Formation of cross-linked poly(2-hydroxypropyl ether) hydrogel measured with iodine that 
reacts with poly(ethylene oxide) (PEO). The assay was performed as described before26 
using PEG 10 kDa for generation of a standard curve. (D) Cross-linking led to a significant 
(p < 0.0001, n = 3, t test) decrease in C3 opsonization. (E,F) Injection of cross-linked 
particles resulted in a decrease in the number of magnetically labeled leukocytes in normal 
C57/BL6 mice, as compared to non cross-linked SPIO NWs. The experiment was repeated 3 
times. (G) Cross-linking did not decrease or even increased the level of C3 opsonization in 
human serum. (H,I) Incubation of cross-linked particles with human leukocytes (as in Figure 
6) resulted in over 60% decrease in the number of magnetically labeled leukocytes. The 
effect of cross-linking on the uptake was variable among different donors, and inhibition 
efficiencies ranging from 30% to 70% were observed (not shown). EDTA inhibited the 
residual uptake of CL-NWs, suggesting the involvement of complement.
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